IGF-1 LR3: A Literature Course in Six Modules

IGF-1 LR3, also written Long R3 IGF-1, is an engineered analogue of insulin-like growth factor-1 (IGF-1). In the peer-reviewed record it appears mainly as a research reagent: something produced in a laboratory and given to animals or expressed in microbial systems so that researchers can study a question. This course is organised into six modules and summarises only what four verified, peer-reviewed papers reported. It makes no recommendation, describes no protocol, and promises no outcome. This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decisions.

Each module closes with an explicit statement of what the evidence cannot support. That structure matters for this particular molecule, because the gap between what is discussed informally about IGF-1 LR3 and what has actually been published in indexed journals is wide.

Module 1: What IGF-1 LR3 Is and How It Has Been Studied

Definition and class

IGF-1 is a naturally occurring peptide hormone of the insulin superfamily. IGF-1 LR3 is not the native hormone; it is a modified version produced by recombinant methods. A 2023 protein-engineering paper handled both molecules side by side, reporting that researchers expressed recombinant IGF-1 and LR3 IGF-1 as fusion proteins with xylanase in the methylotrophic yeast Pichia pastoris (PMID 37261455). That paper places LR3 IGF-1 in the class of recombinant peptide analogues manufactured by microbial expression rather than extracted from tissue.

Origin and production

The same study reported the use of a xylanase fusion partner as an expression strategy for producing IGF-1 and LR3 IGF-1 in yeast (PMID 37261455). Practically, this means the material referred to as "IGF-1 LR3" in the literature is a bioengineered product whose identity, folding and purity depend entirely on the expression and purification system used. Papers of this type exist because making a correctly folded IGF-1 analogue at scale is technically difficult, not because a therapeutic product was being registered.

Forms and models in which it has been studied

Across the verified set, three in-vivo contexts appear. Researchers infused IGF-1 LR3 acutely into fetal sheep and measured pancreatic islet function (PMID 37114757). A separate sheep study administered IGF-1 LR3 to late-gestation growth-restricted fetuses and measured growth (PMID 39679943). A third study used the intranasal route in male 5XFAD transgenic mice, a model of amyloid pathology (PMID 39610283).

Limits of the evidence — Module 1

• The verified set contains no human study of IGF-1 LR3.
• The models used — fetal sheep and transgenic mice — were chosen to answer developmental and neurodegenerative questions, not questions about healthy adults.
• No verified paper characterised material sold outside a research setting, so nothing here speaks to the identity or purity of any non-pharmaceutical supply.

Module 2: Mechanism as Described in the Literature

The cleanest way to describe mechanism for this compound is to describe what the verified studies actually measured after administration, rather than to assert a receptor model the papers did not test.

The insulin-secretion axis

In fetal sheep, the study reported that glucose-stimulated insulin secretion was attenuated during an acute IGF-1 LR3 infusion, and that this attenuation did not persist once islets were isolated and studied ex vivo (PMID 37114757). The dissociation between the in-vivo and the isolated-islet result is mechanistically informative: it suggests the effect observed during infusion was not explained by a lasting change intrinsic to the islets themselves, as reported by the researchers (PMID 37114757).

The growth axis

Because IGF-1 is a growth-associated hormone, the obvious mechanistic prediction is that an analogue would increase fetal growth. The late-gestation sheep study tested that prediction directly and reported that IGF-1 LR3 did not promote growth in growth-restricted fetal sheep (PMID 39679943). A negative result of this kind is part of the mechanistic picture, not an omission from it.

The central-nervous-system readouts

In the mouse work, researchers reported that intranasal long R3 IGF-1 promoted amyloid plaque remodeling in the cerebral cortex while failing to preserve cognitive function in male 5XFAD mice (PMID 39610283). That is a separation between a tissue-level biomarker change and a functional outcome — the biomarker moved, the behaviour did not.

Limits of the evidence — Module 2

• None of the four verified papers reported binding-protein assays, receptor-selectivity data or downstream signalling measurements, so this course does not assert any binding or signalling profile for the analogue.
• No verified study examined skeletal muscle, tendon, satellite cells or body composition in any species.
• Findings in fetal sheep and in a transgenic amyloid mouse model do not transfer automatically to other tissues, ages or species.

Module 3: Reported Outcomes by Study

The table below lists each verified study, the model, the endpoint category and the reported result. Nothing in this module should be read as a benefit claim; two of the three in-vivo studies reported that the primary functional endpoint did not improve.

How to read this pattern

Two independent functional endpoints in two species were reported as null: growth in growth-restricted fetal sheep (PMID 39679943) and cognitive performance in male 5XFAD mice (PMID 39610283). The one clearly positive biological signal in the set — cortical plaque remodeling — was a histological change reported in the same mouse study that found no cognitive preservation (PMID 39610283).

Limits of the evidence — Module 3

• Sample sizes, blinding and statistical power are study-specific and are not reproduced here; the summaries above reflect the conclusions as published.
• No verified study reported performance, strength, recovery, fat mass or lean mass outcomes in any species.
• Null results in specific models do not prove the absence of an effect elsewhere; they establish that the tested effect was not observed under the tested conditions.

Module 4: IGF-1 LR3 Side Effects: What Studies Report

None of the four verified papers was designed as a toxicology or safety study. What exists instead are physiological observations that are safety-relevant, plus explicitly negative efficacy findings.

Metabolic and endocrine observations

The most directly safety-relevant published observation in this set is metabolic: researchers reported that glucose-stimulated insulin secretion was attenuated during an acute IGF-1 LR3 infusion into fetal sheep (PMID 37114757). The same study reported that this attenuation did not persist when islets were isolated and tested outside the animal (PMID 37114757). Interference with normal insulin-secretion dynamics is a recognised concern for IGF-1-family molecules, and this is the endpoint where the verified literature has something concrete to say.

Endpoints that failed to improve

A treatment that changes a biomarker without changing function is a separate category of concern for interpretation. In male 5XFAD mice, the study reported that intranasal long R3 IGF-1 failed to preserve cognitive function despite the reported plaque remodeling in cerebral cortex (PMID 39610283). In growth-restricted fetal sheep, researchers reported no growth promotion (PMID 39679943).

Limits of the evidence — Module 4

• The verified set contains no human adverse-event data, no dose-limiting toxicity analysis, no carcinogenicity study and no long-term exposure data.
• Absence of a reported adverse event in a four-paper set is not evidence of safety; these studies were not powered or designed to detect harms.
• Because the studies used fetal and transgenic-mouse models, the observed physiology may not represent responses in mature, healthy organisms.

Module 5: Pharmacokinetics Where Data Exist

Pharmacokinetics describes absorption, distribution, metabolism and elimination — half-life, clearance, bioavailability, tissue exposure. In the verified set, no paper reported those parameters for IGF-1 LR3.

What can be stated is limited to route and timing as used experimentally. The fetal sheep work used an acute intravascular infusion and evaluated effects both during the infusion and afterwards in isolated islets, with the study reporting that the attenuation of glucose-stimulated insulin secretion did not persist ex vivo (PMID 37114757). The mouse work used the intranasal route, a delivery approach chosen to reach the central nervous system, and researchers reported cortical amyloid plaque remodeling following that treatment (PMID 39610283). The production paper concerned expression and recovery of the recombinant protein rather than its behaviour in a living body (PMID 37261455).

Limits of the evidence — Module 5

• No half-life, clearance, volume of distribution or bioavailability value for IGF-1 LR3 appears in the verified set.
• Route feasibility in an animal model does not establish comparable exposure in other species.
• Any pharmacokinetic figure circulating outside peer review is unverified by the papers cited on this page.

Module 6: Regulatory Status

These are factual statements about regulatory categories; they are not legal advice, and rules differ by jurisdiction and change over time.

Approved products

There is no medicine approved by the US Food and Drug Administration whose active ingredient is IGF-1 LR3. Recombinant human IGF-1 (mecasermin) exists as an approved prescription product for a narrow endocrine indication, but mecasermin is the native-sequence hormone, not the LR3 analogue, and approval of one does not extend to the other.

Research-use-only status

IGF-1 LR3 is distributed in the research supply chain under "research use only" labelling. RUO material is not reviewed for human safety, efficacy, sterility or identity by a drug regulator, and RUO labelling is a statement about intended laboratory use rather than a quality certification. The verified literature reflects exactly this positioning: the papers describe a molecule produced for experimental work (PMID 37261455) and used in animal experiments (PMID 39679943).

Compounding and sport

In the United States, pharmacy compounding under sections 503A and 503B is limited to substances that meet specified statutory criteria, and IGF-1 LR3 is not an ingredient established for that use. In sport, the World Anti-Doping Code prohibits IGF-1 and its analogues under the peptide hormones and growth factors category at all times, in and out of competition.

Limits of the evidence — Module 6

• Regulatory categories describe legal status only; they say nothing about biological effect.
• National rules vary, and the statements above describe general frameworks rather than any individual situation.
• No verified paper addressed regulatory or manufacturing quality standards for material outside a research laboratory.

What the Studies Did Not Test

The honest end point of this course is a list of absences. Across the four verified papers, the following were never tested:

1. Humans. No verified study administered IGF-1 LR3 to human participants.
2. Muscle, strength or body composition. No verified study measured hypertrophy, lean mass, fat mass, performance or recovery.
3. Dosing regimens. No verified study established or compared dose levels, schedules or durations intended for people.
4. Long-term safety. No verified study examined chronic exposure, cancer risk, immunogenicity or organ toxicity.
5. Pharmacokinetics. No half-life or clearance values were reported.
6. Combination use. No verified study examined IGF-1 LR3 alongside other peptides, hormones or medications.
7. Product quality outside the laboratory. No verified study analysed the identity or purity of commercially distributed material.

What the verified literature does contain is a production method in yeast (PMID 37261455), a metabolic observation in fetal sheep (PMID 37114757), a null growth result in growth-restricted fetal sheep (PMID 39679943), and a biomarker-positive but function-negative result in a mouse amyloid model (PMID 39610283). That is the current published picture, and this page does not extend beyond it.

References

• Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris (Applied Microbiology and Biotechnology, 2023)
• Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets (Journal of Developmental Origins of Health and Disease, 2023)
• IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep (American Journal of Physiology. Endocrinology and Metabolism, 2025)
• Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice (Journal of Alzheimer's Disease, 2025)